Search

Displaying results 4241 - 4250 of 7503 in total
  1. Drug

    Ritobegron

    go.drugbank.com/drugs/DB12080
    Investigational

    Ritobegron is under investigation in clinical trial NCT02256735 (Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    RG2417

    go.drugbank.com/drugs/DB05055
    Investigational

    Uridine is synthesized by the mitochondria, the power plant of the human cell responsible for energy metabolism. … The rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research.

  3. Drug

    Ertiprotafib

    go.drugbank.com/drugs/DB06521
    Experimental

    Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes.

  4. Drug

    AT9283

    go.drugbank.com/drugs/DB05169
    Investigational

    AT9283 is an aurora Kinase inhibitor developed by Astex Therapeutics for the treatment of cancer.

  5. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    However, with the introduction of newer drugs with fewer side effects, such as benzodiazepines, the clinical use of methyprylon is now limited. … Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

  6. Drug

    Parasorbic acid

    go.drugbank.com/drugs/DB14121
    Investigational

    Sole constituent of "Vogelbeerol" oil obtained by steam distillation of the acidified juice of the ripe berries of the mountain ash.

  7. Drug

    Amrinone

    go.drugbank.com/drugs/DB01427
    ApprovedWithdrawn

    Amrinone (or inamrinone) is a type 3 pyridine phosphodiesterase inhibitor. It is used in the treatment of congestive heart failure.

  8. Drug

    S-40503

    go.drugbank.com/drugs/DB13938
    Experimental

    S-40503 is an investigational selective androgen receptor modulator (SARM) developed for the treatment of osteoporosis by the Japanese company Kaken Pharmaceuticals.

  9. Drug

    AAV-dXIAP

    go.drugbank.com/drugs/DB17880
    Experimental

    AAV-dXIAP is a recombinant adeno-associated virus-encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP) developed by Neurologix.

  10. Drug

    Alintegimod

    go.drugbank.com/drugs/DB18879
    Investigational

    Alintegimod is under investigation in clinical trial NCT06362369 (A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy).